Journal: Technology and Health Care

Article Title: Prediction and identification of epitopes in the Echinococcus multilocularis thrombospondin 3 antigen

doi: 10.3233/THC-212983

Figure Lengend Snippet: The enzyme-linked immunosorbent assay test on the cytokines of mouse spleen lymphocytes immunized with thrombospondin 3. A: The interleukin-2 test; B: the interferon-y test; C: the tumor necrosis factor- β test; D: the interleukin-4 test; E: the interleukin-17 test. P * ⁣ * * < 0.001.

Article Snippet: PE-labeled anti-mouse IL-4 flow antibody , BD, USA.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Technology and Health Care

Article Title: Prediction and identification of epitopes in the Echinococcus multilocularis thrombospondin 3 antigen

doi: 10.3233/THC-212983

Figure Lengend Snippet: The enzyme-linked immune absorbent spot test of the cytokines of mouse spleen lymphocytes immunized with thrombospondin 3. A: The interleukin-2 test; B: the interferon- γ test; C: the tumor necrosis factor- β test; D: the interleukin-4 test. P * ⁣ * * < 0.001.

Article Snippet: PE-labeled anti-mouse IL-4 flow antibody , BD, USA.

Techniques: Spot Test

Journal: Technology and Health Care

Article Title: Prediction and identification of epitopes in the Echinococcus multilocularis thrombospondin 3 antigen

doi: 10.3233/THC-212983

Figure Lengend Snippet: Experimental reagents

Article Snippet: PE-labeled anti-mouse IL-4 flow antibody , BD, USA.

Techniques: Cell Culture, Labeling, Enzyme-linked Immunosorbent Assay, Enzyme-linked Immunospot

Journal:

Article Title: Role of Natural Killer Cells in Resistance against Friend Retrovirus-Induced Leukemia

doi: 10.1128/JVI.75.7.3152-3163.2001

Figure Lengend Snippet: Changes in the numbers of TER-119+ erythroid cells (a), F-MuLV gp70-expressing cells detected with MAb 720 (b), and CD4+ (c) and CD8+ (d) cells in the spleens of mice inoculated with FV. CB6F1 mice were either immunized with peptide i (○) or given CFA without a peptide (●). Four weeks later, they were inoculated with 150 SFFU of FV. A group of three or four animals were killed at each indicated point, and their spleen cells were subjected to flow-cytometric analyses. Data presented here are means ± SEM. The dashed line in panel b indicates the limit of detection by the flow-cytometric analysis.

Article Snippet: Antibodies and their final concentrations used in the present study were as follows: fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD4 (rat immunoglobulin G2b [IgG2b]; Seikagaku Corporation, Tokyo, Japan) at 0.5 μg/10 6 cells, phycoerythrin (R-PE)-conjugated anti-mouse CD8 (rat IgG2a; Caltag Laboratories, Burlingame, Calif.) at 1 μg/10 6 cells, FITC-conjugated anti-mouse CD69 (hamster IgG; PharMingen, San Diego, Calif.) at 1 μg/10 6 cells, R-PE-conjugated anti-mouse B220 (rat IgG2a; Coulter Immunology, Hialeah, Fla.) at 0.5 μg/10 6 cells, FITC-conjugated anti-NK1.1 (mouse IgG2a; PharMingen) at 2 μg/10 6 cells, biotin-conjugated anti-mouse Pan-NK (DX5, rat IgM; PharMingen) at 1 μg/10 6 cells, and allophycocyanin-conjugated anti-mouse TER-119 (PharMingen) at 0.2 μg/10 6 cells.

Techniques: Expressing

Journal:

Article Title: Role of Natural Killer Cells in Resistance against Friend Retrovirus-Induced Leukemia

doi: 10.1128/JVI.75.7.3152-3163.2001

Figure Lengend Snippet: Detection of cytotoxic effector cells in FV-infected CB6F1 mice. Mice were either immunized with 10 μg of peptide i/mouse or given CFA emulsion without a peptide. B220− spleen cells were separated into CD8+, CD4+, and CD4− CD8− populations, and their cytotoxic activities against FBL-3 (○), Y57-2C (□), and EL-4 (●) cells were tested by incubating the effector and labeled target cells for 12 h. Representative data obtained from a set of experiments performed at PID 9 are shown here, and the results obtained from the six repeated experiments were consistent with these charts.

Article Snippet: Antibodies and their final concentrations used in the present study were as follows: fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD4 (rat immunoglobulin G2b [IgG2b]; Seikagaku Corporation, Tokyo, Japan) at 0.5 μg/10 6 cells, phycoerythrin (R-PE)-conjugated anti-mouse CD8 (rat IgG2a; Caltag Laboratories, Burlingame, Calif.) at 1 μg/10 6 cells, FITC-conjugated anti-mouse CD69 (hamster IgG; PharMingen, San Diego, Calif.) at 1 μg/10 6 cells, R-PE-conjugated anti-mouse B220 (rat IgG2a; Coulter Immunology, Hialeah, Fla.) at 0.5 μg/10 6 cells, FITC-conjugated anti-NK1.1 (mouse IgG2a; PharMingen) at 2 μg/10 6 cells, biotin-conjugated anti-mouse Pan-NK (DX5, rat IgM; PharMingen) at 1 μg/10 6 cells, and allophycocyanin-conjugated anti-mouse TER-119 (PharMingen) at 0.2 μg/10 6 cells.

Techniques: Infection, Labeling

Journal:

Article Title: Role of Natural Killer Cells in Resistance against Friend Retrovirus-Induced Leukemia

doi: 10.1128/JVI.75.7.3152-3163.2001

Figure Lengend Snippet: In vivo depletion of NK cell activity by injection of anti-asialo-GM1 Ab. (a and b) CB6F1 mice immunized with peptide i were injected either with 60 μg of anti-asialo-GM1 Ab each (b) or with normal rabbit serum (a) and were infected with FV. Spleen cells were obtained at PID 9, and the NK cell activity of the B220− population was tested by using YAC-1 (▵) and EL-4 (●) target cells. Data from two separate experiments are shown together here. Injection of higher doses of anti-asialo-GM1 Ab gave the same results when B200− cells were similarly tested for their YAC-1-killing activities. (c and d) Flow cytometric analyses for the expression of the NK cell markers on spleen cells obtained from mice injected with normal rabbit serum (c) or anti-asialo-GM1 Ab (d). Experiments were performed twice and gave essentially the same results as those shown here. (e through j) Cytotoxicity assays using different cell populations isolated from spleen B220− cells of peptide-immunized, FV-infected mice. CD8+, CD4+, and CD4− CD8− populations were purified as described for the experiments shown in Fig. ​Fig.33 from CB6F1 mice injected with anti-asialo-GM1 Ab (f, h, and j) or from those injected with control rabbit serum (e, g, and i). The experiments were performed twice at PID 7 and 9, and the results from the repeated experiments were consistent with the representative data shown here. Target cells used were YAC-1 (Δ), FBL-3 (○), and EL-4 (●).

Article Snippet: Antibodies and their final concentrations used in the present study were as follows: fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD4 (rat immunoglobulin G2b [IgG2b]; Seikagaku Corporation, Tokyo, Japan) at 0.5 μg/10 6 cells, phycoerythrin (R-PE)-conjugated anti-mouse CD8 (rat IgG2a; Caltag Laboratories, Burlingame, Calif.) at 1 μg/10 6 cells, FITC-conjugated anti-mouse CD69 (hamster IgG; PharMingen, San Diego, Calif.) at 1 μg/10 6 cells, R-PE-conjugated anti-mouse B220 (rat IgG2a; Coulter Immunology, Hialeah, Fla.) at 0.5 μg/10 6 cells, FITC-conjugated anti-NK1.1 (mouse IgG2a; PharMingen) at 2 μg/10 6 cells, biotin-conjugated anti-mouse Pan-NK (DX5, rat IgM; PharMingen) at 1 μg/10 6 cells, and allophycocyanin-conjugated anti-mouse TER-119 (PharMingen) at 0.2 μg/10 6 cells.

Techniques: In Vivo, Activity Assay, Injection, Infection, Expressing, Isolation, Purification

Journal:

Article Title: Role of Natural Killer Cells in Resistance against Friend Retrovirus-Induced Leukemia

doi: 10.1128/JVI.75.7.3152-3163.2001

Figure Lengend Snippet: Cytotoxic activity of a CD4+ T-cell clone, SB14-31, specific for an F-MuLV env-encoded epitope. (a) SB14-31 cells were incubated with various target cells with or without preincubation with peptide fn. 51Cr release during 4 h of incubation at an E:T ratio of 20 was measured. (b) LB 27.4 target cells were either incubated with the indicated Ab-binding peptides after 51Cr labeling or infected with the indicated recombinant vaccinia virus for 16 h at a multiplicity of infection of 10 and then labeled. Pretreated LB 27.4 cells were then incubated with SB14-31 cells for 4 h at an E:T ratio of 20:1. Experiments were performed at least twice at various E:T ratios, and the results were consistent with the representative data shown here.

Article Snippet: Antibodies and their final concentrations used in the present study were as follows: fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD4 (rat immunoglobulin G2b [IgG2b]; Seikagaku Corporation, Tokyo, Japan) at 0.5 μg/10 6 cells, phycoerythrin (R-PE)-conjugated anti-mouse CD8 (rat IgG2a; Caltag Laboratories, Burlingame, Calif.) at 1 μg/10 6 cells, FITC-conjugated anti-mouse CD69 (hamster IgG; PharMingen, San Diego, Calif.) at 1 μg/10 6 cells, R-PE-conjugated anti-mouse B220 (rat IgG2a; Coulter Immunology, Hialeah, Fla.) at 0.5 μg/10 6 cells, FITC-conjugated anti-NK1.1 (mouse IgG2a; PharMingen) at 2 μg/10 6 cells, biotin-conjugated anti-mouse Pan-NK (DX5, rat IgM; PharMingen) at 1 μg/10 6 cells, and allophycocyanin-conjugated anti-mouse TER-119 (PharMingen) at 0.2 μg/10 6 cells.

Techniques: Activity Assay, Incubation, Binding Assay, Labeling, Infection, Recombinant

Journal:

Article Title: Role of Natural Killer Cells in Resistance against Friend Retrovirus-Induced Leukemia

doi: 10.1128/JVI.75.7.3152-3163.2001

Figure Lengend Snippet: Cytotoxic activities of four different CD4+ T-cell clones specific for peptide i. T-cell clones F5-5 (a), FP3-10 (b), FP8-7 (c), and FP10-16 (d) were tested for their ability to lyse LB 27.4 target cells by incubation at the indicated E:T ratios for 3 h. LB 27.4 cells were incubated either with peptide i (□, ○, ▵) or with the control peptide of the same length, ie (●). Killing assays were performed in the absence (○, ●) or presence of anti-CD4 (□) or anti-CD8 (▵) MAb. Assays were performed at least twice, and the results were consistent with the representative data shown here.

Article Snippet: Antibodies and their final concentrations used in the present study were as follows: fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD4 (rat immunoglobulin G2b [IgG2b]; Seikagaku Corporation, Tokyo, Japan) at 0.5 μg/10 6 cells, phycoerythrin (R-PE)-conjugated anti-mouse CD8 (rat IgG2a; Caltag Laboratories, Burlingame, Calif.) at 1 μg/10 6 cells, FITC-conjugated anti-mouse CD69 (hamster IgG; PharMingen, San Diego, Calif.) at 1 μg/10 6 cells, R-PE-conjugated anti-mouse B220 (rat IgG2a; Coulter Immunology, Hialeah, Fla.) at 0.5 μg/10 6 cells, FITC-conjugated anti-NK1.1 (mouse IgG2a; PharMingen) at 2 μg/10 6 cells, biotin-conjugated anti-mouse Pan-NK (DX5, rat IgM; PharMingen) at 1 μg/10 6 cells, and allophycocyanin-conjugated anti-mouse TER-119 (PharMingen) at 0.2 μg/10 6 cells.

Techniques: Clone Assay, Incubation

Journal:

Article Title: Role of Natural Killer Cells in Resistance against Friend Retrovirus-Induced Leukemia

doi: 10.1128/JVI.75.7.3152-3163.2001

Figure Lengend Snippet: In vivo depletion of asialo-GM1+ cells and its effect on T cells and protective immunity against FV infection induced by peptide immunization. (a through d) Mice used for the experiments whose results are shown in Fig. ​Fig.77 were also analyzed for the presence of CD4+ and CD8+ T cells in the spleen and their ability to mount viral-antigen-specific CD4+ T-cell responses. Flow-cytometric analyses for the expression of CD4 and CD8 were performed by using pooled whole spleen cells obtained from the mice injected with anti-asialo-GM1 Ab (b) or normal rabbit serum (a). Experiments were performed twice at PID 7 and 9, and results obtained from the repeated experiments were consistent with the representative data shown here. Numbers indicate percentages of CD4+ and CD8+ cells among live nucleated spleen cells. B220− CD8− CD4+ T cells purified for the experiments whose results are shown in Fig. ​Fig.7g7g and h were also tested for their proliferative activities in response to stimulation with peptide i. CD4+ T cells purified from the mice injected with anti-asialo-GM1 Ab (d) and those purified from control mice given normal rabbit serum (c) were incubated with X-irradiated syngeneic spleen cells and the indicated amount of peptide i (○). As controls, the CD4+ T cells purified from the anti-asialo-GM1 Ab-injected mice were also stimulated with an endogenous retroviral env-derived peptide ie (●) and the influenza virus nucleoprotein-derived peptide NP366–374 (▵). Experiments were performed twice, and results obtained from the repeated experiments were consistent with the representative data shown here. (e) Development of FV-induced leukemia in CB6F1 mice immunized with peptide i. Mice were either immunized with 10 μg of peptide i each (○, ▵, □) or given CFA alone (●). Two groups of the immunized mice were then injected with anti-asialo-GM1 Ab (▵) or control rabbit serum (□), while the remaining group (○) was not injected with any Ab. All mice were inoculated with 150 SFFU of FV.

Article Snippet: Antibodies and their final concentrations used in the present study were as follows: fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD4 (rat immunoglobulin G2b [IgG2b]; Seikagaku Corporation, Tokyo, Japan) at 0.5 μg/10 6 cells, phycoerythrin (R-PE)-conjugated anti-mouse CD8 (rat IgG2a; Caltag Laboratories, Burlingame, Calif.) at 1 μg/10 6 cells, FITC-conjugated anti-mouse CD69 (hamster IgG; PharMingen, San Diego, Calif.) at 1 μg/10 6 cells, R-PE-conjugated anti-mouse B220 (rat IgG2a; Coulter Immunology, Hialeah, Fla.) at 0.5 μg/10 6 cells, FITC-conjugated anti-NK1.1 (mouse IgG2a; PharMingen) at 2 μg/10 6 cells, biotin-conjugated anti-mouse Pan-NK (DX5, rat IgM; PharMingen) at 1 μg/10 6 cells, and allophycocyanin-conjugated anti-mouse TER-119 (PharMingen) at 0.2 μg/10 6 cells.

Techniques: In Vivo, Infection, Expressing, Injection, Purification, Incubation, Irradiation, Derivative Assay

Journal: Journal of Nanobiotechnology

Article Title: Circadian disruption and ROS-NLRP3 signaling mediate sleep deprivation-enhanced silica nanoparticle toxicity in lacrimal glands

doi: 10.1186/s12951-025-03630-5

Figure Lengend Snippet: Impact of SiNPs and SD + SiNPs treatment on immune cells and genes in murine ELGs. (A) Representative immunohistochemical images of CD4 + T cells in murine ELGs at ZT0 and ZT12, from NC, SiNPs-treated and SiNPs + SD-treated groups. Scale bar : 20 μm. (B) Representative immunohistochemical images of CD8 + T cells in murine ELGs at ZT0 and ZT12, from the NC, SiNPs-treated, and SD + SiNPs-treated groups. Scale bar : 50 μm. (C) Quantitative analysis of CD4 + T cell in murine ELGs, comparing the diurnal variation of positive cell ratio among the NC group, the SiNPs-treated group and the SD + SiNPs-treated group. ** P < 0.01. (D) Average abundance of CD4 + T cell in murine ELGs from the NC, the SiNPs-treated and the SD + SiNPs-treated groups. Statistical analysis was performed using the Kruskal–Wallis test (non-parametric), followed by Dunn’s post hoc test for multiple comparisons. * P < 0.05, *** P < 0.001. (E) Quantitative analysis of CD8 + T cell in murine ELGs, comparing the diurnal variation of positive cell ratio among NC group, SiNPs-treated group and SD + SiNPs-treated group. For NC group, P = 0.3391. For SiNPs-treated group, P = 0.4931. For SD + SiNPs-treated group, P = 0.0001. * P < 0.05, ** P < 0.01, *** P < 0.001. NS: not significant. (F) Average abundance of CD8 + T cells in murine ELGs from NC, SiNPs-treated and SD + SiNPs-treated groups. ** P < 0.01. (G) Heatmaps of diurnal expression for immune-related DEGs between the NC group and SiNPs-treated group in murine ELGs. The expression levels of immune-related genes were obtained from RNA-Seq and expression range of DEGs was normalized to ± 3. (H) The PPINs and functional clusters (cluster 1–3) with relevant KEGG pathways of immune-related genes between the SiNPs-treated group and SD + SiNPs-treated group. (I) The top 10 KEGG pathways enriched histogram of immune-related genes with P < 0.05 were displayed. (J) Immunoblotting of phosphorylation of STAT3, JAK2, phosphorylation of IκBα and p65, and IL17A in ELGs at ZT0 and ZT12, from NC, SiNPs-treated and SD + SiNPs-treated groups

Article Snippet: For immunohistochemistry, ELG sections of the NC, SiNPs-treated, and SD + SiNPs-treated groups were washed and blocked in 3% bovine serum albumin (Cat no. G5001, Servicebio Company, Wuhan, China) in PBS at pH 7.4 and incubated overnight at 4 °C with anti-CD4 antibody (Cat no. GB13064-2, Servicebio Company, Wuhan, China), anti-CD8 antibody (Cat no. GB13429, Servicebio Company, Wuhan, China), anti-NLRP3 antibody (Cat no. 68102-1-Ig, Proteintech, Wuhan, China), anti-ASC antibody (Cat no. ab309497, Abcam, USA), anti-γ-H2Ax antibody (Cat no. 7631 T; Cell Signaling Technology, Inc.), anti-beta III tubulin monoclonal antibody (Cat. no. GB12139; Servicebio Company, Wuhan, China).

Techniques: Immunohistochemical staining, Expressing, RNA Sequencing, Functional Assay, Western Blot, Phospho-proteomics

Journal: Viruses

Article Title: Role of T Cells in Vaccine-Mediated Immunity against Marek's Disease.

doi: 10.3390/v15030648

Figure Lengend Snippet: Figure 1. T Cells depletion. Flow cytograms show the percentage of CD4+ and CD8+ T Cells in the control (Panel A), CD4+ T Cell depleted birds (Panel B), CD8+ T Cell depleted birds (Panel C), and CD4+/CD8+ T Cell depleted birds (Panel D) 11 days post-treatment. Blood samples from three birds per group were pooled, PBMC isolated, and 1 × 106 cells/100 µL was used for cell surface antigen analysis. The CD4+ T Cells were stained with CD4-PE, and CD8+ T Cells were stained with CD8α-FITC,

Article Snippet: Anti-CD4 m onuclear cell binding spe ficity. (A): Histopaque 1077-treated PBMC (1 × 106 cells) with no added antibodies (negative control); (B): PBMC stained with mouse antichicken CD4-PE antibody (Southern Biotech, positive control); (C): PBMC stained with rat anti-mouse IgM-PE/CY7 antibody (secondary antibody only); (D): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 1.5 μg per 1 × 106 cells) and the secondary rat anti-mouse IgM-PE/CY7 antibody; (E): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 0.298 μg per 1× 106) and the secondary rat anti-mouse IgM-PE/CY7 antibody.

Techniques: Control, Isolation, Staining

Journal: Viruses

Article Title: Role of T Cells in Vaccine-Mediated Immunity against Marek's Disease.

doi: 10.3390/v15030648

Figure Lengend Snippet: Figure 2. Recovery of CD4+ and CD8+ T Cells 13 days post-termination of antibody treatment. The percentage population of CD4+ and CD8+ T Cells in the control birds (Panel A), CD4+ T Cell depleted birds (Panel B), and CD8+ T Cell depleted group (Panel C) are depicted 13 days post-termination of antibody treatment. Blood samples from three birds per group were pooled, PBMC isolated, and 1 × 106 cells/100 µL was used for cell surface antigen analysis. The CD4+ T Cells were stained with CD4-PE, and CD8+ T Cells were stained with CD8α -FITC, 11–39 monoclonal antibodies. (Panel D) Bar graphs showing the percentage of B and T Cell populations 13 days after termination of antibody treatment. Comparative analysis was made between the untreated control and the T Cell depleted birds. Same total blood samples were used for the staining of B cells and double staining of CD4+, and CD8+ T Cells. B cells, CD4+ T Cells, and CD8+ T Cells were stained with monoclonal antibodies Bu1-RPE, CD4-PE, and CD8α -FITC, respectively. V: vaccinated; C: challenged.

Article Snippet: Anti-CD4 m onuclear cell binding spe ficity. (A): Histopaque 1077-treated PBMC (1 × 106 cells) with no added antibodies (negative control); (B): PBMC stained with mouse antichicken CD4-PE antibody (Southern Biotech, positive control); (C): PBMC stained with rat anti-mouse IgM-PE/CY7 antibody (secondary antibody only); (D): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 1.5 μg per 1 × 106 cells) and the secondary rat anti-mouse IgM-PE/CY7 antibody; (E): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 0.298 μg per 1× 106) and the secondary rat anti-mouse IgM-PE/CY7 antibody.

Techniques: Control, Isolation, Staining, Bioprocessing, Double Staining

Journal: Viruses

Article Title: Role of T Cells in Vaccine-Mediated Immunity against Marek's Disease.

doi: 10.3390/v15030648

Figure Lengend Snippet: Figure 3. PCR-based analysis of viral DNA in spleen samples of control and treated birds at 5 days post-inoculation (dpi, Panel A), 10 dpi (Panel B), 20 dpi (Panel C), and 57 dpi (Panel D). The viral genome detection in the non-vaccinated challenged birds (Lanes 14, 15, and 16) is depicted by green arrows. The detection of pp38 in the T Cell depleted, vaccinated, and challenged birds (lanes 2–13) is shown by red arrows. Lanes: M, DNA ladder, 1: Control bird, 2–4: Birds with intact T Cell, vaccinated, challenged, 5–7: Birds with CD4+ T Cell depleted, vaccinated, challenged, 8–10: Birds with CD8+ T Cell depleted, vaccinated, challenged, 11–13: Birds with CD4+/CD8+ T Cell depleted, vaccinated, challenged, 14–16: Birds with intact T Cells, non-vaccinated, challenged, 17: Positive control for pp38 amplification using MDV DNA isolated from infected birds (blue arrow), 18: GAPDH (blue arrow), M: DNA ladder.

Article Snippet: Anti-CD4 m onuclear cell binding spe ficity. (A): Histopaque 1077-treated PBMC (1 × 106 cells) with no added antibodies (negative control); (B): PBMC stained with mouse antichicken CD4-PE antibody (Southern Biotech, positive control); (C): PBMC stained with rat anti-mouse IgM-PE/CY7 antibody (secondary antibody only); (D): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 1.5 μg per 1 × 106 cells) and the secondary rat anti-mouse IgM-PE/CY7 antibody; (E): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 0.298 μg per 1× 106) and the secondary rat anti-mouse IgM-PE/CY7 antibody.

Techniques: Control, Positive Control, Isolation, Infection

Journal: Viruses

Article Title: Role of T Cells in Vaccine-Mediated Immunity against Marek's Disease.

doi: 10.3390/v15030648

Figure Lengend Snippet: Figure 4. Anti-CD4 mononuclear cell binding specificity. (A): Histopaque 1077-treated PBMC (1 × 106 cells) with no added antibodies (negative control); (B): PBMC stained with mouse anti- chicken CD4-PE antibody (Southern Biotech, positive control); (C): PBMC stained with rat anti-mouse IgM-PE/CY7 antibody (secondary antibody only); (D): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 1.5 µg per 1 × 106 cells) and the secondary rat anti-mouse IgM-PE/CY7 antibody; (E): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 0.298 µg per 1 × 106) and the secondary rat anti-mouse IgM-PE/CY7 antibody. The gated green cells in the middle of panels (D,E) are staining the same population of cells as in the middle of panel B.

Article Snippet: Anti-CD4 m onuclear cell binding spe ficity. (A): Histopaque 1077-treated PBMC (1 × 106 cells) with no added antibodies (negative control); (B): PBMC stained with mouse antichicken CD4-PE antibody (Southern Biotech, positive control); (C): PBMC stained with rat anti-mouse IgM-PE/CY7 antibody (secondary antibody only); (D): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 1.5 μg per 1 × 106 cells) and the secondary rat anti-mouse IgM-PE/CY7 antibody; (E): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 0.298 μg per 1× 106) and the secondary rat anti-mouse IgM-PE/CY7 antibody.

Techniques: Binding Assay, Negative Control, Staining, Positive Control, Isolation

Journal: Viruses

Article Title: Role of T Cells in Vaccine-Mediated Immunity against Marek's Disease.

doi: 10.3390/v15030648

Figure Lengend Snippet: Figure 6. Immunohistochemical analysis of MDV antigen in the skin samples of all vaccinated and challenged groups with intact or depleted T Cells. Anti-gB monoclonal antibody was used for detection of virus particles in the skin tissues of challenged groups. (Panel A) depicts skin sample from an unvaccinated, challenged bird with intact T Cells showing significant viral replication in the FFE (blue arrow). (Panel B) represents the skin sample from a vaccinated/challenged bird with intact T Cells showing minor MDV antigen in the FFE (arrows). (Panel C) depicts skin sample from a CD4+ T Cell depleted, vaccinated/challenged bird that exhibits minor viral replication in the FFE (blue arrow). The replication rate of MDV in the skin of a CD8+ T Cell depleted bird is depicted in (Panel D) (arrows). (Panel E) shows the replication rate of MDV in the skin sample of a CD4+/CD8+

Article Snippet: Anti-CD4 m onuclear cell binding spe ficity. (A): Histopaque 1077-treated PBMC (1 × 106 cells) with no added antibodies (negative control); (B): PBMC stained with mouse antichicken CD4-PE antibody (Southern Biotech, positive control); (C): PBMC stained with rat anti-mouse IgM-PE/CY7 antibody (secondary antibody only); (D): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 1.5 μg per 1 × 106 cells) and the secondary rat anti-mouse IgM-PE/CY7 antibody; (E): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 0.298 μg per 1× 106) and the secondary rat anti-mouse IgM-PE/CY7 antibody.

Techniques: Immunohistochemical staining, Virus

Journal: Viruses

Article Title: Role of T Cells in Vaccine-Mediated Immunity against Marek's Disease.

doi: 10.3390/v15030648

Figure Lengend Snippet: Figure 7. The picture depicts the chest bone (keeled sternum) of a CD4+/CD8+ T Cell depleted bird that is severely emaciated (Panel A). These birds exhibit no clinical signs of MD during the experiment and no T Cell lymphoma at termination. The birds experienced breathing difficulties. (Panel B) shows the spleen of a CD4+/CD8+ T Cell depleted bird at termination. Left: spleen from a CD4+ T Cell depleted bird; right: spleen from CD4+/CD8+ T Cell depleted bird. This contrasts with MDV-infected birds where the spleen is enlarged (splenomegaly), and the thymus and bursa are atrophied. (Panel C) depicts the bursa of a CD4+/CD8+ T Cell depleted bird. Although the spleen tissues from these birds were negative for MDV genome, the bursas, like the spleens, were severely atrophied. Left: bursa from a CD4+ T Cell depleted bird; right: bursa from a CD4+/CD8+ T Cell depleted bird.

Article Snippet: Anti-CD4 m onuclear cell binding spe ficity. (A): Histopaque 1077-treated PBMC (1 × 106 cells) with no added antibodies (negative control); (B): PBMC stained with mouse antichicken CD4-PE antibody (Southern Biotech, positive control); (C): PBMC stained with rat anti-mouse IgM-PE/CY7 antibody (secondary antibody only); (D): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 1.5 μg per 1 × 106 cells) and the secondary rat anti-mouse IgM-PE/CY7 antibody; (E): PBMC stained with primary monoclonal antibody isolated from hybridoma cell line (IgM, at 0.298 μg per 1× 106) and the secondary rat anti-mouse IgM-PE/CY7 antibody.

Techniques: Infection